Epic Sciences, Inc. announced that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered...
Lucid Diagnostics Inc, a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed In , announced that, the MolDX Program published a Future Effective...
